We performed a 5-question survey of 40 hematology-oncology specialists in the US to gauge current prescribing practices and physician experience with reimbursement for ibrutinib and idelalisib for the treatment of patients with CLL.
Published: January 27, 2015
Number of pages:15
We performed a 5-question survey of 22 hematology-oncology specialists in the U.S. to gain insight on current prescribing practices for Chronic Lymphocytic Leukemia (CLL). Topics covered in this survey include:
Current usage of monoclonal antibodies and oral kinase inhibitors for CLL treatment
Comparison of expected future prescribing practices with predicted 2014 usage patterns from a December 2013 survey
Drugs covered include: Imbruvica (ibrutinib, PCYC/JNJ), Zydelig (idelalisib, GILD), venetoclax/ABT-199 (ABBV and Roche), Gazyva (obinutuzumab, Roche), and others
Chronic Lymphocytic Leukemia (CLL) #2: Drug Usage and Reimbursement
Breakdown of Surveyed Hematology-Oncology Specialists
Of the CLL patients you saw in the last 3 months, how many were at the following stages of treatment? [numerical free response]
Approximately what percentage of your CLL patients have the following types of medical insurance as their primary coverage? [numerical free response, answers must sum to 100%]
In the last 3 months, how many of your patients received the following treatment in the given lines of treatment? [numerical free response]
What are your impressions of reimbursement for ibrutinib in the following treatment groups, based on your experience with patients in your practice? [grid single-answer]
What are your impressions of reimbursement for idelalisib+rituximab in the following treatment groups, based on your experience with patients in your practice? [grid single-answer]
Appendix: Oral TKI Market Opportunity by Indication
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.